pI: 5.3217 |
Length (AA): 399 |
MW (Da): 43612 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 307 | 3h5a (A) | 49 | 356 | 22.00 | 0 | 1 | 0.950905 | 0.34 |
31 | 220 | 1tt5 (A) | 1 | 177 | 19.00 | 0 | 0.78 | 0.61319 | 0.22 |
59 | 354 | 5iaa (A) | 68 | 346 | 66.00 | 0 | 1 | 1.31675 | 0.14 |
61 | 194 | 5l6h (A) | 431 | 567 | 31.00 | 0.00000045 | 1 | 0.63774 | -0.53 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_130165)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G05350 | NAD(P)-binding Rossmann-fold superfamily protein |
Babesia bovis | BBOV_III005200 | ThiF family protein |
Brugia malayi | Bm1_36180 | CG1749-PA |
Caenorhabditis elegans | CELE_T03F1.1 | Protein T03F1.1 |
Cryptosporidium hominis | Chro.40221 | hypothetical protein |
Cryptosporidium parvum | cgd4_1960 | ThiF/moeB family |
Dictyostelium discoideum | DDB_G0293306 | E1-like enzyme family protein |
Drosophila melanogaster | Dmel_CG1749 | CG1749 gene product from transcript CG1749-RA |
Echinococcus granulosus | EgrG_000471100 | ubiquitin modifier activating enzyme 5 |
Echinococcus multilocularis | EmuJ_000471100 | ubiquitin modifier activating enzyme 5 |
Homo sapiens | ENSG00000081307 | ubiquitin-like modifier activating enzyme 5 |
Leishmania braziliensis | LbrM.15.1010 | NAD/FAD dependent dehydrogenase, putative |
Leishmania donovani | LdBPK_151030.1 | NAD/FAD dependent dehydrogenase, putative |
Leishmania infantum | LinJ.15.1030 | NAD/FAD dependent dehydrogenase, putative |
Leishmania major | LmjF.15.0970 | NAD/FAD dependent dehydrogenase, putative |
Leishmania mexicana | LmxM.15.0970 | NAD/FAD dependent dehydrogenase, putative |
Loa Loa (eye worm) | LOAG_02702 | ubiquitin-activating enzyme 5 |
Mus musculus | ENSMUSG00000032557 | ubiquitin-like modifier activating enzyme 5 |
Neospora caninum | NCLIV_031950 | thiF family domain-containing protein, putative |
Oryza sativa | 4329438 | Os02g0506500 |
Schistosoma japonicum | Sjp_0311700 | Ubiquitin-like modifier-activating enzyme 5, putative |
Schistosoma japonicum | Sjp_0096390 | Ubiquitin-like modifier-activating enzyme 5, putative |
Schistosoma japonicum | Sjp_0216860 | expressed protein |
Schistosoma mansoni | Smp_045780 | ubiquitin-activating enzyme E1-related |
Schmidtea mediterranea | mk4.003153.02 | Ubiquitin-like modifier-activating enzyme 5 |
Trypanosoma brucei gambiense | Tbg972.9.3130 | NAD/FAD dependent dehydrogenase, putative,ubiquitin-activating enzyme, putative |
Trypanosoma brucei | Tb927.9.6040 | E1-like ubiquitin-activating enzyme, putative |
Trypanosoma congolense | TcIL3000_9_2040 | E1-like ubiquitin-activating enzyme, putative |
Trypanosoma congolense | TcIL3000_0_07900 | E1-like ubiquitin-activating enzyme, putative |
Trypanosoma cruzi | TcCLB.505843.40 | E1-like ubiquitin-activating enzyme, putative |
Trypanosoma cruzi | TcCLB.509353.10 | E1-like ubiquitin-activating enzyme, putative |
Toxoplasma gondii | TGME49_231940 | ThiF family protein |
Theileria parva | TP02_0433 | hypothetical protein, conserved |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.160.4430 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.4430 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.4430 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.4430 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_231940 | Toxoplasma gondii | Probably non-essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.